

Edgar Filing: AMARIN CORP PLC\UK - Form 6-K

AMARIN CORP PLC\UK  
Form 6-K  
June 18, 2003

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUERS PURSUANT TO RULE  
13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT  
OF 1934

Dated: June 18, 2003

Commission file number 0-21392

AMARIN CORPORATION PLC  
(Exact name of Registrant as Specified in its Charter)

ENGLAND  
(Jurisdiction of Incorporation or  
organization of Issuer)

7 Curzon Street  
London W1J 5HG, England  
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files  
or will file annual reports under cover of Form 20-F or  
Form 40-F.

Form 20-F                       Form 40-F

Indicate by check mark whether the registrant by  
furnishing the information contained in this Form is  
also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes                                       No

Attachment:

Material Events

(a)        Amarin Corporation and Acadia Pharmaceuticals Sign Pharmaceutical  
Development Agreement.

This report on Form 6-K is hereby incorporated  
by reference in the registration statement on Form F-3  
(Registration Statement No. 333-12642) of Amarin  
Corporation plc and in the prospectus contained therein,  
and in the Registration Statement on Form F-3  
(Registration No. 333-13200) of Amarin Corporation plc  
and in the prospectus contained therein, and this report  
on Form 6-K shall be deemed a part of each such  
registration statement from the date on which this  
report is filed, to the extent not superseded by

Edgar Filing: AMARIN CORP PLC\UK - Form 6-K

documents or reports subsequently filed.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMARIN CORPORATION PLC

By: /s/ Richard A B Stewart  
Richard A B Stewart  
Chief Executive Officer

Date: June 18, 2003

Index to

Exhibits

Exhibit Item	Sequentially Numbered Page
(a) Material Event description-	4

Exhibit (a)

Contacts:

Rick Stewart	Stefan Ohlsson
Chief Executive Officer	Managing Director
Amarin Corporation plc	Amarin Development A.B.
Phone: +44 (0) 20 7907 2440	Phone: +46 40 539800
Email: rick.stewart@amarincorp.com	Email: stefan.ohlsson@amarindev.se

AMARIN CORPORATION AND ACADIA PHARMACEUTICALS SIGN PHARMACEUTICAL DEVELOPMENT AGREEMENT

London, United Kingdom, 18th June 2003 - Amarin Corporation plc (NASDAQ: AMRN) today confirmed that its Swedish subsidiary, Amarin Development AB, has been engaged to provide pharmaceutical formulation and manufacturing services for ACADIA Pharmaceuticals, based in San Diego, California and Copenhagen, Denmark. The deal centers on the continued development of ACADIA's small molecule drug candidate ACP-103, currently in Phase I clinical studies. ACADIA intends to utilize Amarin's services in connection with additional clinical studies planned for ACP-103 for the treatment of neuropsychiatric and neurological disorders.

## Edgar Filing: AMARIN CORP PLC\UK - Form 6-K

Rick Stewart, CEO of Amarin, commented on the successful deal, "The selection of Amarin Development by ACADIA to provide these services underscores our strengthened position as a global product development company. This agreement additionally makes use of Amarin's expertise in neurology and complements the research and development activities of Amarin Pharmaceuticals Inc. in the US, making this a particularly attractive signing."

### About ACP-103

ACP-103 is initially being pursued as a therapy for treatment-induced dysfunctions in Parkinson's disease, an indication that lacks adequate drug therapy. Due to its unique profile, ACP-103 may also have broad utility in a range of other important indications. ACP-103 is a proprietary small molecule that acts as a selective inverse agonist at the 5-HT<sub>2A</sub> receptor.

### About Amarin

Amarin Corporation plc is a specialty pharmaceutical company focused on neurology and pain management. Amarin has multiple pharmaceutical products on the US market along with a development pipeline that includes two late-stage candidates: Zelapar (selegiline HCl orally disintegrating tablets) for Parkinson's disease and LAX-101, a proprietary compound for Huntington's Disease. For press releases and other Company information, visit our websites at <http://www.amarincorp.com> and <http://www.amarinpharma.com>.

### About ACADIA

ACADIA Pharmaceuticals is a drug discovery and development company that efficiently discovers novel small molecule drug candidates using its proprietary chemical-genomics platform. ACADIA has applied its platform to generate a broad discovery pipeline directed at large unmet medical needs including Parkinson's disease, chronic pain, psychosis, and glaucoma. Two of ACADIA's drug candidates have been successfully advanced from initial discovery to clinical development, and several additional programs are in late-stage preclinical testing. ACADIA's corporate headquarters as well as its biological research facilities are located in San Diego, California and its chemistry research facilities are located in Copenhagen, Denmark.

Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties which may cause the Company's actual results in future periods to be materially different from any performance suggested herein. Such risks and uncertainties include, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development and commercialization, the impact of competitive products and patents, as well as other risks and uncertainties detailed from time to time in periodic report, including but not limited to the filing or approval of the NDA for Zelapar. For more information, please refer to Amarin Corporation's Annual Report for 2002 on Form 20-F and its Form 6-Ks as filed with the U.S. Securities and Exchange Commission. The Company assumes no obligation to update information on its expectations.